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Abstract Charcot–Marie–Tooth disease (CMT) is the
most common inherited neuropathy with heterogeneous
clinical presentation and genetic background. The axonal
form (CMT2) is characterised by decreased action potentials
indicating primary axonal damage. The underlying pathol-
ogy involves axonal degeneration which is supposed to be
related to axonal protein dysfunction caused by various gene
mutations. The overlapping clinical manifestation of CMT2
with distal hereditary motor neuropathy (dHMN) and
intermediate CMT causes further diagnostic difficulties.
Aminoacyl-tRNA synthetases have been implicated in the
pathomechanism of CMT2. They have an essential role in
protein translation by attaching amino acids to their cognate
tRNAs. To date six families have been reported worldwide
with dominant missense alanyl-tRNA synthetase (AARS)
mutations leading to clinically heterogeneous axonal neu-
ropathies. The pathomechanism of some variants could be
explained by impaired amino acylation activity while other
variants implicating an editing defect need to be further in-
vestigated. Here, we report a cohort of six additional families
originating from the United Kingdom and Ireland with
dominant AARS-related neuropathies. The phenotypic
manifestation was distal lower limb predominant sensori-
motor neuropathy but upper limb impairment with split hand
deformity occasionally associated. Nerve conduction studies
revealed significant demyelination accompanying the axonal
lesion in motor and sensory nerves. Five families have the
c.986G[A, p.(Arg329His) variant, further supporting that
this is a recurrent loss of function variant. The sixth family, of
Irish origin, had a novel missense variant, c.2063A[G,
p.(Glu688Gly). We discuss our findings and the associated
phenotypic heterogeneity in these families, which expands
the clinical spectrum of AARS-related neuropathies.
Keywords Charcot–Marie–Tooth disease (CMT) 
Axonal neuropathy  Aminoacyl-tRNA synthetases (ARS) 
Alanyl-tRNA synthetase (AARS)
Introduction
Charcot–Marie–Tooth disease (CMT) is a clinically and
genetically heterogeneous group of peripheral neuropathies
characterised by symmetric atrophy and weakness in the
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distal muscles, areflexia and variable range of sensory
impairment. In respect of its worldwide prevalence of an
estimated 1:2500, CMT is considered to be the most
common cause of inherited peripheral neuropathies. Based
on the electrophysiological and pathological characteristics
it can be classified further into a demyelinating form
(CMT1), where the nerve conduction velocity is reduced
due to altered myelination, and to an axonal form (CMT2),
where the primary axonal dysfunction leads to reduced
amplitudes of evoked muscle action potentials. The inter-
mediate form (CMTI) shares both features [1, 11, 13].
There have been more than 90 genes associated with CMT
so far and, despite the overlapping phenotypes, some cer-
tain genes manifest with distinctive forms dependent on
their contribution to Schwann cell and axonal functions [3].
Genetic diagnosis is particularly difficult to achieve in
the axonal form (CMT2) which shows genotypic and
phenotypic overlap with distal hereditary motor neu-
ropathies (dHMN) or distal spinal muscular atrophy
(dSMA), a subgroup of rare inherited motor axonal neu-
ropathies with no significant sensory involvement [9].
Similarly, dominant intermediate CMT (DI-CMT) cases
presenting with intermediate nerve conduction velocities of
25–45 m/s are also frequently misdiagnosed as CMT2 [6].
There have been 15 genes or loci described in relation to
CMT2 [5]. Some of these genes have been already asso-
ciated with axonal dysfunction, such as mitofusin 2
(MFN2) which is responsible for 5–10 % of CMT2 cases,
neurofilament light chain (NEFL) in 1–5 % and gan-
glioside-induced differentiation-associated protein
(GDAP1) in less than 1 % of the cases [1, 3, 4, 11, 13].
Aminoacyl-tRNA synthetases (ARS) are essential en-
zymes in the translation of the genetic code by attaching
amino acids to their cognate tRNAs during protein syn-
thesis [3, 5, 7]. There are 37 nuclear genes encoding ARSs
for cytoplasmic or mitochondrial protein synthesis. Muta-
tions in six genes encoding aminoacyl-tRNA synthetases
(ARS) have been implicated in axonal pathology [3]. The
majority of the mutations were described in glycyl-tRNA
synthetase (GARS, MIM#600287) causing CMT2 type D
(CMT2D) or distal spinal muscular atrophy type V (dSMA-
V), both are autosomal dominant upper limb predominant
motor axonal neuropathies. Mutations in tyrosyl-tRNA
synthetase (YARS, MIM#603623) were reported in domi-
nant intermediate CMT type C (CMTDIC). The relevance
of methionyl-tRNA synthetase (MARS, MIM#156560) and
histidyl-tRNA synthetase (HARS, MIM#142810) muta-
tions for CMT is supported by strong functional and evo-
lutionary evidence, yet incomplete segregation and absence
of additional unrelated cases warrant future studies to
substantiate this conclusion [2, 14]. Compound heterozy-
gous lysyl-tRNA synthetase (KARS, MIM#601421) muta-
tions were present in one patient with recessive
intermediate CMT type B (CMTIRB) manifesting as part
of a more complex neurological condition [3, 7, 15].
To date only six families have been described in the
literature with dominant missense mutations in the alanyl-
tRNA synthetase (AARS, MIM#601065) leading to
clinically heterogeneous phenotypes (Table 1). The
c.986G[A, p.(Arg329His) variant was reported as a re-
current mutation in two unrelated French families pre-
senting with variable age of onset distal sensorimotor
degeneration secondary to predominant axonal neuropathy
and with absent or slight demyelination [5]. The same
AARS variant was identified in a large Australian family
with early onset axonal neuropathy, variable sensorineural
deafness and foot deformities, accompanied by intermedi-
ate nerve conduction velocities [7]. Another Australian
family with the c.2333A[C, p.(Glu778Ala) variant
manifested as sensorimotor axonal neuropathy with rip-
pling muscles and cramps in the proband, while only rip-
pling muscles were present in three affected relatives [7].
In a Taiwanese pedigree pure axonal neuropathy with
variable age of onset was associated with the c.211A[T,
p.(Asn71Tyr) AARS variant [6]. In a three generation
dominant Chinese family the c.2677G[A, p.(Asp893Asn)
mutation was related to a distal motor neuropathy (dHMN)
phenotype based on neurogenic EMG findings [15]. Ad-
ditionally autosomal recessive loss of function AARS mu-
tations (compound heterozygous p.Lys81Thr and
p.Arg751Gly and homozygous p.Arg751Gly) were also
described in two unrelated families, causing severe infan-
tile epileptic encephalopathy with a central myelin defect
and peripheral neuropathy [12].
Here, we report a cohort of multigenerational British
and Irish families with autosomal dominant neuropathies
and missense mutations in AARS, with the aim of ex-
panding the clinical spectrum and providing further pheno-
genotypic correlations in AARS-related neuropathies.
Methods
Patients
Clinical description and examination findings of the af-
fected patients from 4 UK and 2 Irish families diagnosed
with AARS-related neuropathy are provided in detail in
Table 1 and Fig. 1 and in the Supplementary data.
Electrophysiology
Nerve conduction studies and needle electromyography
were performed in the probands and in additional affected
relatives from the UK and Irish families.
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Genetic studies
Genetic testing was performed in the Bristol Genetics
Laboratory, using the UK Genetic Testing Network ap-
proved approach; a multi-gene panel assay utilising next
generation sequencing (NGS). Genomic DNA was extracted
from the peripheral white blood cells obtained from pro-
bands of all families according to standard methods. En-
richment was performed using a custom-designed 330 kb
SureSelect capture (Agilent Technologies) targeting 56 ge-
nes associated with inherited peripheral neuropathy (IPN).
Libraries were prepared from genomic DNA according to the
manufacturer’s protocol and sequenced on an Illumina
MiSeq (2 9 150 bp). For data analysis and filtering, a be-
spoke open-source pipeline using BWA and GATK was used
to align data to the reference human genome (UCSC hg19).
Variant classification was based on Association for Clinical
Genetic Science (ACGS) Practice Guidelines (2013). Can-
didate pathogenic variants were confirmed by Sanger Se-
quencing using an Applied Biosystems 3730 analyser.
Consent
All participants provided written informed consent to be
involved in this study which was approved by local re-
search ethics committees.
Results
Patients
Due to overlapping and variable clinical phenotypes the
referrals were occasionally misleading indicating CMT1,
I.
II.
III.
1
1 4 6
1
UK Family 1
1
1 2
1
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II.
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UK Family 3
I.
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III.
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1
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II
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3
1 2
Irish Family 2
A
B
Fig. 1 a Pedigrees of UK and Irish families. Arrows the index
patients of each family. b Image of patient II/4 in UK family 1
showing predominantly lower limb symptoms manifesting with
bilateral pes cavus and severe feet drop. Index patient of the same
UK1 family (III/1) representing moderate intrinsic hand muscles
wasting accompanied by lower limb distal wasting and weakness.
Image of patient (II.1) from UK family 3 showing severe bilateral foot
drop and distal muscle wasting
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hereditary sensory neuropathy or intermediate CMT
phenotypes. Multi-gene panel testing was performed in a
total of 22 patients with ‘mixed/intermediate’ CMT and
out of the 8 positives 5 were proved to be an AARS
mutation.
Lower limb predominant sensorimotor neuropathy was
characteristic in UK family 1. All family members devel-
oped pes cavus and foot drop bilaterally leading to pro-
gressive walking difficulties at different adult ages. They
all remained ambulant with orthotic support. Various de-
gree of upper limb involvement was observed. The proband
manifested with fluctuating weakness of finger and intrinsic
hand muscles at disease onset with progressive hand
muscles wasting at later stage.
Slowly progressive various degree of motor weakness
affecting the lower extremities and subsequent walking
problems were the leading symptoms in UK family 2.
Tiptoe walking and feet deformities were present. Sensory
changes were mild or absent and no upper limb involve-
ment was associated, but we note that the index patient is
only 20 years of age.
In UK family 3, the clinical presentation was very
heterogeneous. The proband manifested with young adult
onset asymmetric upper and lower limb involvement
equally affecting motor and sensory functions. His father
had stable feet deformities since childhood which pro-
gressed rapidly in his late 50s exclusively and symmetri-
cally affecting his lower limbs causing predominantly
motor and milder sensory loss. Development of bilateral
foot drop and walking difficulties were common symptoms
within the family.
A slowly progressive disease course and predominant
lower limb motor loss was the common presentation in
UK family 4. Initial symptoms presented either in sym-
metric or asymmetric fashion and striking clinical features
were bilateral foot and toe drop with subsequent walking
difficulties. Various degrees of weakness and wasting of
intrinsic hand muscles with split hand formation were
associated. Mild to moderate sensory changes were
present.
Lower limb motor symptoms progressed slowly in Irish
family 1 leading to different impact on their walking
abilities with ambulatory loss in some family members.
Sensory loss in lower extremities accompanied and upper
limb involvement manifested in later ages.
Early onset slowly progressive and predominantly motor
impairment affecting both upper and lower extremities was
observed in Irish family 2. Toe walking and bilateral foot
drop were common features. Associated milder sensory
changes became apparent at later ages. Wasting and
weakness of intrinsic hand muscles resulted in split hand
deformity (Fig. 1; Table 2).
Electrophysiology
A series of nerve conduction studies was performed in the
proband (III.1) of UK family 1. Initially the multifocal
patchy demyelinating changes with conduction block
leading to the dispersion of the motor neuronal conduction
velocities were more suggestive of CIDP, but CSF protein
was normal and the patient did not improve on immuno-
suppressive therapy. Previous recordings indicated inter-
mediate motor neuropathy both demyelinating and axonal
in nature with multifocal patchy characteristics and severe
sensory polyneuropathy. Family members (II.4 and II.6)
had intermediate nerve conduction velocities indicating
both demyelinating and axonal features. The proband
(III.1) of UK family 2 showed both demyelinating and
axonal sensorimotor neuropathy with nerve conduction
velocities in the intermediate range. The index patient
(III.1) of UK family 3 had intermediate nerve conduction
studies underlying his progressive asymmetrical distal
sensorimotor neuropathy symptoms. The proband (II.2) of
UK family 4 had motor conduction velocities in the de-
myelinating range consistent with demyelinating CMT
(CMT1). Nerve conduction studies in his father (I.1) also
showed profound demyelinating neuropathy with sig-
nificant axonal loss. Testing of both his affected brothers
(II.3 and II.5) revealed severe predominantly axonal pe-
ripheral sensorimotor neuropathy with reduced conduction
velocities. Neurophysiology in the Irish families confirmed
length-dependent motor and sensory neuropathy with in-
termediate conduction velocities (Supplementary Table).
Genetic studies
Clinical characteristics and electrophysiology findings
were directive in the candidate gene testing. Mutations in
genes involved in axonal pathology (MPZ, MFN2, NEFL,
GDAP1) and common demyelinating genes (PMP22,
MPZ) were excluded in all patients. Upper limb involve-
ment at disease onset and split hand deformity indicated
exclusion of mutations in the GARS gene. Early onset
lower extremity predominant motor symptoms jointly with
Achilles contracture urged us to exclude the recently re-
ported bicaudal D homolog 2 (BICD2)-related neuropathy.
Prominent sensory manifestation in some patients indicated
screening for SPTLC1 mutations.
With the use of IPN 56 gene panel assay we identified
the previously described pathogenic variant in exon 8 of
the AARS gene (c.986G[A, p.Arg329His) in all 4 UK and
in Irish family 1. We identified another AARS variant
(c.2063A[G, p.Glu688Gly) which to date has not been
reported in the literature, as the cause of the dominant
sensorimotor neuropathy manifesting in the second family
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originated from Ireland. This variant is not recorded in
dbSNP, 1000 genomes, Exome Variant Server or Exome
Aggregation Consortium. Alignment of protein sequences
from multiple species supported that glutamic acid 688 is
highly conserved among all species from E.coli to H.s-
apiens. In silico prediction tools indicate this missense
change as likely deleterious (SIFT: deleterious; Polyphen2:
probably pathogenic; Mutation Taster disease causing).
The variant segregated with disease in this family sup-
porting pathogenicity (Fig. 2).
Discussion
Aminoacyl-tRNA synthetases (ARSs) catalyse a two-step
aminoacylation reaction by binding and activating amino
acids and conjugate them with their cognate tRNA mole-
cules [3]. Their essential role in keeping the fidelity of the
genetic code during protein translation explains why ARSs
are ubiquitous and highly conserved amongst species [5].
Several hypotheses have been proposed in the mechanisms
of ARS-related CMT pathology. Most mutations are mis-
sense amino acid substitutions leading to dominant CMT
phenotypes [3, 7]. In vitro aminoacylation assays indicate
both quantitative error via impaired enzyme activation, and
qualitative defects by non-cognate bindings. Yeast viability
assays investigated in vivo functional consequences of the
ARS mutations and support a loss of function effect. Pro-
tein localisation studies show altered distribution of some
of the ARS proteins in cultured neurons suggesting spa-
tially inappropriate protein synthesis [3, 7, 9].
Alanyl–aminoacyl-tRNA synthetase (AARS) consists of
21 exons and encodes 968 amino acids. From the N-ter-
minal to the C-terminal it has an aminoacylation or cat-
alytic domain (AD), helical or tRNA-binding domain (HD)
and editing domain (ED). Unlike as in other ARSs, the
acceptor arm of tRNAAla can be directly recognised by the
catalytic site of AARS. The editing domain was evolu-
tionarily integrated in the AARS with the aim of
eliminating mischarged tRNAAla. Therefore, AARS has
highly conserved sequence in all of its domains across
species from E. coli to H. sapiens [5, 15].
In the literature, AARS mutations have been reported
affecting all three domains. The p.(Asn71Tyr) AARS mu-
tation, which was described in a Taiwanese pedigree, is
located in the aminoacylation domain and both in vitro and
in vivo assays revealed impaired aminoacylation activity
result in reduced charging capacity [6, 7]. The recurrent,
p.(Arg329His) mutation located in the middle helical do-
main of AARS has been largely investigated. Haplotype
analysis in 2 French and 1 Australian family with
Arg329His AARS mutation demonstrated a different
Fig. 2 Sequenced c.986G[A missense mutation in AARS in affected UK and Irish index patients. Illustrated positions of AARS mutations and
conservation of affected residues across species
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founder for all three families. A methylation-mediated
process gives rise to this recurrent mutation which was also
found to associate with impaired enzyme activity. AARS
exon 8, which contains the p.(Arg329His) variant, has a
highly methylated CpG site and considered to be a muta-
tional hot spot [7]. In the cohort reported here, this was the
most common AARS mutation affecting one Irish and four
UK families. A limited haplotype analysis of four poly-
morphic variants in the proximity of the causative AARS
mutation showed identical haplotype for all four North UK
families, and close similarity was suggested (3/4 identical
variants) in the Irish family. These data imply that the
p.(Arg329His) mutation is potentially a founder mutation
in the five reported families (data not shown). The phe-
notypic manifestation was rather heterogeneous within the
families despite the same genotypic background. However,
lower limb predominance was characteristic in all families;
significant upper limb involvement with split hand (selec-
tive atrophy of thenar muscles) could not be ignored in
some patients similar to GARS-related pathology. Acute or
sub-acute episodes of worsening, resembling acquired
neuropathies were also reported. Compared to the previ-
ously reported pedigrees, nerve conduction studies in our
families showed greater demyelination process accompa-
nying the always present axonal dysfunction. Sensory re-
sponses were frequently severely impaired along with
occasional clinically significant sensory loss. Similar to the
French pedigree, we observed asymmetric distribution of
the symptoms in some of the patients, but in contrast to the
Australian cohort, sensorineural deafness was not present
in either of the families (Tables 1, 2). There have been two
different phenotypes described so far in relation to the
AARS editing domain mutations. The p.(Glu778Ala) vari-
ant manifesting in an Australian family with dominant
rippling muscle disease, did not involve an evolutionarily
conserved amino acid within the AARS editing domain and
impairment in the editing capacity also could not be proven
[7]. In a Chinese pedigree, the p.(Asp893Asn) mutation led
to a dominant pure motor pathology causing dHMN. It was
found to reside in a highly conserved sequence of the
C-terminal editing domain and prediction programs indi-
cated deleterious pathogenicity [15]. In our cohort, we
identified a novel AARS variant which also locates to the
AARS editing domain. The clinical phenotype related to
p.(Glu688Gly) is of an early onset length-dependent motor
and sensory neuropathy. Neurophysiology, similar to our
families with the p.Arg329His mutation, showed interme-
diate conduction velocities. In the proband, there was also
more marked involvement of FDIO and APB than ADM,
suggesting a split hand phenotype. Functional studies
would be necessary to further analyse the pathogenicity of
this variant and its impact on the editing capacity of the
enzyme.
Nothing indicates better the variability of AARS-related
pathology than an utmost recent paper, published during the
revision of our manuscript, which describes a novel heterozy-
gous missense c.304G[C (p.Gly102Arg) AARS variant
manifesting with a novel myeloneuropathy phenotype in a large
family [8]. This warrants that genetic screening toward AARS
and other aminoacyl-tRNA synthetase mutations might be al-
ways considered in axonal neuropathology.
Conclusions
AARS-related neuropathy was identified in a cohort of
dominant UK and Irish families by multi-gene panel ap-
proach. Our cohort supports that the p.(Arg329His) AARS
variant is a recurrent mutation presenting worldwide. The
associated phenotypic spectrum is heterogeneous and may
cause difficulties in achieving diagnosis based only on
clinical examination, underlying the valuable contribution
of next generation sequencing.
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